Cara Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-07-02
- Employees
- 55
- Market Cap
- $19.6M
- Introduction
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
- Conditions
- PruritusNotalgia Paresthetica
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT05978063
- Locations
- 🇪🇸
Cara Therapeutics Study Site, Madrid, Spain
🇵🇱Cara Therapeutics Study Site 2, Katowice, Poland
CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients
- Conditions
- Hemodialysis
- Interventions
- Drug: CR845 0.5 mcg/kgOther: Placebo
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05533008
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Minneapolis, Minnesota, United States
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
- Conditions
- PruritusAtopic Dermatitis
- Interventions
- Drug: TCS CreamDrug: PlaceboDrug: Vehicle Cream
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 287
- Registration Number
- NCT05387707
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Morgantown, West Virginia, United States
🇺🇸Cara Therapeutics Study Site 2, Santa Monica, California, United States
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Conditions
- Chronic Kidney DiseasesPruritus
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT05356403
- Locations
- 🇪🇸
Cara Therapeutics Study Site, Vitoria, Spain
🇪🇸Cara Therapeutics Study Site 2, Valencia, Spain
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Conditions
- Chronic Kidney DiseasesPruritus
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 286
- Registration Number
- NCT05342623
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Hampton, Virginia, United States
🇺🇸Cara Therapeutics Study Site 2, Houston, Texas, United States
🇺🇸Cara Therapeutics Study Sites, Corsicana, Texas, United States
Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin
- Conditions
- Uremic Pruritus
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Cara Therapeutics, Inc.
- Registration Number
- NCT05031546
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)
- Conditions
- Notalgia ParestheticaPruritus
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04706975
- Locations
- 🇨🇦
Cara Therapeutics Study Site, Winnipeg, Canada
Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04019574
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Dallas, Texas, United States
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
- Conditions
- PruritusAtopic Dermatitis
- Interventions
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 401
- Registration Number
- NCT04018027
- Locations
- 🇨🇦
Cara Therapeutics Study Site, Montréal, Quebec, Canada
🇺🇸Cara Therapeutics Study Site 2, Austin, Texas, United States
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
- Conditions
- Uremic Pruritus
- Interventions
- Drug: CR845 0.5 mcg/kg
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT03998163
- Locations
- 🇵🇱
Cara Therapeutics Study Site, Sochaczew, Poland
🇭🇺Cara Therapeutics Study Site 2, Budapest, Hungary
🇺🇸Cara Therapeutics Study Site 3, San Antonio, Texas, United States